Forbes June 5, 2024
Dave Wessner

An FDA advisory committee recommended the development of a new Covid-19

vaccine at its meeting on Wednesday. According to the panel, vaccine manufacturers should design updated vaccines to target the JN.1 variant of SARS-CoV-2. Ideally, these updated vaccines will be available in the fall.

The Vaccines and Related Biological Products Advisory Committee of the FDA evaluated the effectiveness of the current vaccines and discussed the need for a new vaccine formulation. Representatives from Moderna, Pfizer-BioNtech, and Novavax presented data about the protection offered by current vaccines against emerging variants and the potential benefits of vaccines specifically targeting these new strains.

Following the presentations and a period of public comment, the panel voted unanimously to recommend that the 2024-2025 Covid-19 vaccine...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article